Floatz logo

Izaflortaucipir

Frontotemporal Dementia

University of PennsylvaniaSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Frontotemporal Dementia cohort.

Asset / SponsorPhaseRating
Flortaucipir
Mayo Clinic
Phase 4BBB
Fludeoxyglucose
University of Michigan
Phase 4BB
Citalopram
Sunnybrook Health Sciences Centre
Phase 4BB
Lemborexant
Nova Scotia Health Authority
Phase 4BB
Pittsburgh Compound B Unlabelled
Mayo Clinic
Phase 4BB

View all 38 →

Same molecule, other indications

Izaflortaucipir is also rated in:

Alzheimer diseaseActive
BB
Indicative · Phase 3
65 / 100
View asset →
Parkinson diseaseActive
CCC
Indicative · Phase 2
55 / 100
View asset →
cognitive disorderDormant
CCC
Indicative · Phase 2
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →